The firm – which specialising in software for new product research and development (R&D) and consulting services – said the office is the result of a hefty rise in demand from its American customers.
CEO Alex Drijver told Outsourcing-Pharma.com one of the biggest reasons for the uptick in business was the launch of two new desktop applications – JChem and JChem for Excel.
“The success of these has encouraged us to look to expand our suite of applications,” he said.
He added that the decision to locate the office in Boston – a “biotechnology hub” – was based on a need to provide more local services in regions which generate the most business.
“Locating in this key US pharma-biotech hub helps us ensure our technology evolves with customer requirements, and they gain more business value from their chemistry,” he said.
“We are also increasingly involved in projects with both smaller biotech companies and large pharma to migrate their systems from their earlier legacy systems to the ChemAxon platform. As a result there is an increasing need for local support and also consultancy services.”
Drijver added that as many of the clients do not have the in-house capabilities for the “specific integrations or custom applications” ChemAxon is recruiting more technical specialists to help.
He could not reveal the companies the re-enforced services would be aimed at, but told us the company lists the top 15 pharma amongst its clients.
More to come
Drijver said developing strong collaborative relationships with a range of US firms – from the large pharma, large and small biotech, agrochem, and fine chemicals sectors – is key to the company’s future growth strategy.
“ChemAxon continues to grow its customer base year on year, of which the US accounts for around 35 per cent,” he said.
He also told us the firm plans to open another US office soon in California, either in San Diego or the Bay Area hubs “where we are already very active.”